Last reviewed · How we verify
Azacitidine associated with Lenalidomide
Azacitidine is a DNA methyltransferase inhibitor.
Azacitidine is a DNA methyltransferase inhibitor. Used for Myelodysplastic syndromes, Acute myeloid leukemia.
At a glance
| Generic name | Azacitidine associated with Lenalidomide |
|---|---|
| Sponsor | Assistance Publique - Hôpitaux de Paris |
| Drug class | DNA methyltransferase inhibitor |
| Target | DNA methyltransferase |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
Azacitidine works by inhibiting DNA methyltransferase enzymes, leading to hypomethylation of DNA and subsequent reactivation of silenced genes. This mechanism is thought to contribute to its therapeutic effects in myelodysplastic syndromes and acute myeloid leukemia.
Approved indications
- Myelodysplastic syndromes
- Acute myeloid leukemia
Common side effects
- Fatigue
- Nausea
- Diarrhea
- Cough
- Pyrexia
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |